These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12079390)

  • 41. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden.
    Soares ML; Coelho T; Sousa A; Holmgren G; Saraiva MJ; Kastner DL; Buxbaum JN
    Eur J Hum Genet; 2004 Mar; 12(3):225-37. PubMed ID: 14673473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy.
    Vita G; Mazzeo A; Di Leo R; Ferlini A
    Neuromuscul Disord; 2005 Mar; 15(3):259-61. PubMed ID: 15725588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients.
    Altland K; Winter P; Sauerborn MK
    Electrophoresis; 1999 Jun; 20(7):1349-64. PubMed ID: 10424456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.
    Lim KH; Dasari AKR; Ma R; Hung I; Gan Z; Kelly JW; Fitzgerald MC
    Biochemistry; 2017 Sep; 56(36):4808-4818. PubMed ID: 28820582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Destabilization of transthyretin by pathogenic mutations in the DE loop.
    Takeuchi M; Mizuguchi M; Kouno T; Shinohara Y; Aizawa T; Demura M; Mori Y; Shinoda H; Kawano K
    Proteins; 2007 Feb; 66(3):716-25. PubMed ID: 17143887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative MD analysis of the stability of transthyretin providing insight into the fibrillation mechanism.
    Sørensen J; Hamelberg D; Schiøtt B; McCammon JA
    Biopolymers; 2007 May; 86(1):73-82. PubMed ID: 17315201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Amyloidogenesis of variant transthyretin in familial amyloidotic polyneuropathy].
    Miyazato M; Nakazato M; Matsukura S
    No To Shinkei; 1994 May; 46(5):425-31. PubMed ID: 8060681
    [No Abstract]   [Full Text] [Related]  

  • 48. [Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)].
    Nakamura M; Ando Y
    Rinsho Byori; 2004 Oct; 52(10):804-12. PubMed ID: 15624495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined liver-kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment.
    Lobato L; Beirão I; Seca R; Pessegueiro H; Rocha MJ; Queiroz J; Gomes M; Henriques AC; Teixeira M; Almeida R
    Amyloid; 2011 Jun; 18 Suppl 1():190-2. PubMed ID: 21838483
    [No Abstract]   [Full Text] [Related]  

  • 50. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
    Zhang Q; Kelly JW
    Biochemistry; 2003 Jul; 42(29):8756-61. PubMed ID: 12873136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
    Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
    Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met.
    Dardiotis E; Koutsou P; Zamba-Papanicolaou E; Vonta I; Hadjivassiliou M; Hadjigeorgiou G; Cariolou M; Christodoulou K; Kyriakides T
    J Neurol Sci; 2009 Sep; 284(1-2):158-62. PubMed ID: 19493541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diagnosis of familial amyloid polyneuropathy type I in Argentina].
    Pérez G; Romero MC; Trigo P; Lendoire J; Imventarza O; Nesse A
    Medicina (B Aires); 2008; 68(4):273-81. PubMed ID: 18786882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin.
    Altland K; Winter P; Saraiva MJ; Suhr O
    Neurogenetics; 2004 Feb; 5(1):61-7. PubMed ID: 14534839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods.
    Simões CJ; Mukherjee T; Brito RM; Jackson RM
    J Chem Inf Model; 2010 Oct; 50(10):1806-20. PubMed ID: 20883031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pathogenesis and therapy for transthyretin related amyloidosis].
    Ando Y; Jono H
    Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL; Leme LP; Busnardo RG; Foguel D
    J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective silencing of a mutant transthyretin allele by small interfering RNAs.
    Kurosawa T; Igarashi S; Nishizawa M; Onodera O
    Biochem Biophys Res Commun; 2005 Nov; 337(3):1012-8. PubMed ID: 16225852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin.
    Liu K; Kelly JW; Wemmer DE
    J Mol Biol; 2002 Jul; 320(4):821-32. PubMed ID: 12095258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular consequences of transthyretin deposition.
    Saraiva MJ
    Amyloid; 2003 Aug; 10 Suppl 1():13-6. PubMed ID: 14640036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.